blinatumomab,ponatinib
otsuka,amgen,takeda,astellas,incyte
['blinatumomab', 'ponatinib', 'ph+ all']
data has made the rounds over these last few months but impressive presentation from on the data from caveats apply, short follow up, no comparator arm, n=40, but i suspect we will look back on this as being practice changing #ash2022 
Assistant Professor Leukemia Program @weillcornell @nyphospital @wcmleukemia | Novel therapeutics and improving outcomes in AML and ALL